Tango Therapeutics, INC Schedule 13G passive stakes

Tango Therapeutics, Inc. has filed an amendment to its Schedule 13G, detailing beneficial ownership as of June 30, 2026, with reporting persons holding 0.0% of the class.

TCG Crossover Fund II, L.P., along with affiliated entities and individual Chen Yu, has increased its beneficial ownership in Tango Therapeutics, Inc. to 7.0%, acquiring 10,147,867 shares.

Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC have filed a Schedule 13G, reporting beneficial ownership of 6.0% of Tango Therapeutics, Inc. common stock as of June 30, 2026.

Woodline Partners LP has disclosed a beneficial ownership of 4,000,567 shares, representing 2.5% of the outstanding common stock of Tango Therapeutics, Inc.

Farallon Capital Management and affiliated entities have reported beneficial ownership of 9.8% of Tango Therapeutics' common stock, primarily through warrants and shares.

Adage Capital Management, L.P. and associated individuals have reported beneficial ownership of 5,600,000 shares, representing 3.44% of Tango Therapeutics, Inc. common stock.

Nextech Crossover I SCSp and associated individuals have filed a Schedule 13G reporting a 5.1% beneficial ownership stake in Tango Therapeutics, Inc.

Woodline Partners LP has reported beneficial ownership of 8,000,013 shares, representing 5.6% of the outstanding common stock of Tango Therapeutics, Inc., as of March 31, 2026.

RTW Investments, LP and Roderick Wong report beneficial ownership of 9.3% of Tango Therapeutics, Inc. common stock as of March 31, 2026.

Adage Capital Management, L.P. has reported beneficial ownership of 12,809,485 shares of Tango Therapeutics, Inc. common stock, representing 8.98% of the class.

Farallon Capital Management entities have reported beneficial ownership of over 7.8% of Tango Therapeutics' common stock, including shares underlying warrants.

FMR LLC reports beneficial ownership of 6.9% of Tango Therapeutics Inc. common stock as of March 31, 2026.

Invus Group entities and Raymond Debbane have collectively reported beneficial ownership of 5,657,105 shares, representing 4.0% of Tango Therapeutics' common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Tango Therapeutics Inc. following an internal realignment.

Invus Public Equities, Avicenna Life Sci Master Fund, and related entities, including Raymond Debbane, reported beneficial ownership of 6.1% of Tango Therapeutics, Inc. common stock as of December 31, 2025.

Adage Capital Management, along with Robert Atchinson and Phillip Gross, reported a 7.88% beneficial ownership stake in Tango Therapeutics, Inc. as of December 31, 2025.

Farallon Capital Management and its affiliates filed an amended Schedule 13G for Tango Therapeutics, Inc., disclosing beneficial ownership of 9.99% of common stock and changes in its internal managing members.

The Vanguard Group reported a 5.01% beneficial ownership stake in Tango Therapeutics Inc. as of December 31, 2025, alongside an internal realignment of its reporting structure.

BlackRock, Inc. has reported a 6.3% beneficial ownership stake in Tango Therapeutics, Inc., holding 8,477,165 shares of common stock as of December 31, 2025.

TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu have filed an amended Schedule 13G, disclosing a 6.3% beneficial ownership in Tango Therapeutics, Inc.

Adage Capital Management and its principals reported a passive 2.26% beneficial ownership stake in Tango Therapeutics, Inc. as of September 30, 2025.

Farallon Capital Management and its affiliates have reported a collective beneficial ownership of 9.7% of Tango Therapeutics' common stock.

Raymond Debbane and affiliated entities, collectively known as The Invus Group, have disclosed a 5.3% beneficial ownership stake in Tango Therapeutics, Inc.

Woodline Partners LP has disclosed a 5.6% passive ownership stake in Tango Therapeutics, Inc., holding over 6 million shares of common stock.

Farallon Capital and its affiliated entities have disclosed a collective beneficial ownership of 8.4% in Tango Therapeutics, Inc. common stock.

Adage Capital Management, L.P. and its principals, Robert Atchinson and Phillip Gross, have disclosed a beneficial ownership of 5.45% in Tango Therapeutics, Inc. common stock.

BlackRock, Inc. has disclosed a 5.0% passive beneficial ownership stake in Tango Therapeutics, Inc. common stock, totaling 5,457,030 shares.

Farallon Capital and its affiliated entities have filed a Schedule 13G, revealing a collective beneficial ownership of 7,182,000 shares, representing 6.6% of Tango Therapeutics, Inc.'s common stock.

EcoR1 Capital, LLC, along with its affiliates and control person Oleg Nodelman, has reported a continued beneficial ownership of 9.9% in Tango Therapeutics, Inc. as of December 31, 2024.